

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2022

**Olema Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction  
of incorporation)

001-39712  
(Commission  
File Number)

30-0409740  
(I.R.S. Employer  
Identification No.)

512 2nd Street, 4th Floor  
San Francisco, California  
(Address of principal executive offices)

94107  
(Zip Code)

(415) 651-3316

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	OLMA	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 16, 2022, Olema Pharmaceuticals, Inc. (the “**Company**”) held its annual meeting of stockholders (the “**Annual Meeting**”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2022 (the “**Proxy Statement**”).

**Proposal 1—Election of Directors**

Nominees	Final Voting Results		
	For	Withheld	Broker Non-Votes
Cynthia Butitta	25,158,671	2,427,936	2,442,960
Cyrus Harmon, Ph.D.	24,729,582	2,857,025	2,442,960
Graham Walmsley, M.D., Ph.D.	25,116,924	2,469,683	2,442,960

The Company’s stockholders elected each of the three nominees for Class II director to hold office until the Company’s 2025 annual meeting of stockholders and until their respective successors have been duly elected and qualified.

**Proposal 2—Advisory Vote on Executive Compensation**

For	Against	Abstain	Broker
			Non-Votes
21,851,764	3,812,824	1,922,018	2,442,960

The Company’s stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.

**Proposal 3—Advisory Vote on the Frequency of Stockholder Votes on Executive Compensation**

1 Year	Final Voting Results			Abstain
	2 Years	3 Years		
25,259,988	1,746	411,608	1,913,265	

The stockholders indicated, on an advisory basis, the preferred frequency of every year for future stockholder advisory votes regarding compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement. In light of the vote of the stockholders on this proposal and consistent with the recommendation of the Company’s Board of Directors, the Company will include a non-binding stockholder advisory vote to approve the compensation of its named executive officers in its proxy materials every year. The Company will hold such annual advisory votes until the next required vote on the frequency of stockholder votes on named executive officer compensation. The Company is required to hold votes on the frequency of holding future non-binding advisory votes on executive compensation every six calendar years.

**Proposal 4—Ratification of Selection of Independent Registered Public Accounting Firm**

For	Final Voting Results		Abstain
	Against		
28,072,697	26,193	1,930,677	

The Company’s stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022.

No other matters were submitted for stockholder action.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OLEMA PHARMACEUTICALS, INC.**

Dated: June 23, 2022

By: /s/ Shane Kovacs

Shane Kovacs

Chief Operating and Financial Officer

---